Two things really stand out for me about this article.
First of all, it’s obviously a well researched and balanced write up, which I really appreciate. There is nothing new is in the article for anyone who has been here for a while, but thats to be expected. This is the type of article I will (and am) sending to friends who know I take rapamycin but who have been slow to follow m. I encourage people here to do the same.
Secondly I was surprised that the journalist used a biohacker who buys his rapamycin from India as the key “user experience” in the story. Usually major news periodicals don’t feature biohackers so prominently, and I am glad they did. Our poll of our visitors suggests that the India pharmacy route is around 50 % of the people and perhaps increasing as we hear about health insurance rejections due to longevity medicine use by our members here.
I will also just make a note for people… I think we are hitting the inflection point for longevity drugs going mainstream. In the past year we have seen articles covering (or at least mentioning) rapamycin from The Economist magazine, the Wall Street Journal, Bloomberg BusinessWeek, Fortune Magazine, GQ magazine, USA Today, and now The Washington Post. Last year I also heard that The NY Times had a journalist contacting people as part of a story on rapamycin, but apparently it never ran.
The trend line is clear. We’re still at the fringe of the healthcare market, but the fringe is growing…